Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation , today announced that its phase III study of REVLIMID^ in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival .
http://www.benzinga.com/news/13/07/3744904/celgene-reports-phase-iii-study-of-oral-revlimid-in-newly-diagnosed-multiple-myel
http://www.benzinga.com/news/13/07/3744904/celgene-reports-phase-iii-study-of-oral-revlimid-in-newly-diagnosed-multiple-myel
No comments:
Post a Comment